Sakemura RL, Manriquez Roman C, Horvei P, et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024;143(3):258-271.
出版信息
Blood. 2024 Oct 3;144(14):1544. doi: 10.1182/blood.2024026723.
Abstract
摘要
相似文献
1
Sakemura RL, Manriquez Roman C, Horvei P, et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024;143(3):258-271.酒村RL、曼里克兹·罗曼C、霍韦伊P等。塔法西他单抗与CD19的结合增加了CART19细胞疗法的治疗指数并减轻了CRS的严重程度。《血液》。2024年；143(3):258 - 271。
Blood. 2024 Oct 3;144(14):1544. doi: 10.1182/blood.2024026723.
2
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.塔法西单抗与 CD19 结合增加了 CART19 细胞疗法的治疗指数，并降低了 CRS 的严重程度。
Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905.
3
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.新型抗 CD19 嵌合抗原受体 T 细胞产品针对 CD19 近膜区，具有快速的 ON 和 OFF 速率，用于治疗非霍奇金淋巴瘤的安全性和有效性：一项首次人体研究。
Mol Cancer. 2023 Dec 9;22(1):200. doi: 10.1186/s12943-023-01886-9.
4
5
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.在复发或难治性弥漫性大B细胞淋巴瘤的CD19导向嵌合抗原受体T细胞疗法之前使用塔法昔单抗的真实世界应用。
Biomark Res. 2025 Jan 23;13(1):18. doi: 10.1186/s40364-024-00706-6.
6
Preclinical study of CD19 detection methods post tafasitamab treatment.治疗后检测 CD19 方法的临床前研究。
Front Immunol. 2023 Oct 20;14:1274556. doi: 10.3389/fimmu.2023.1274556. eCollection 2023.
7
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.GM-CSF 抑制可减少细胞因子释放综合征和神经炎症，但增强异种移植物中的 CAR-T 细胞功能。
Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21.
8
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.双特异性抗体武装的 CD19 CAR T 细胞增强对实体瘤的细胞毒性：概念验证研究。
J Cancer Res Clin Oncol. 2020 Aug;146(8):2007-2016. doi: 10.1007/s00432-020-03260-4. Epub 2020 May 24.
9
Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice.在NSG小鼠中对靶向CD19的嵌合抗原受体修饰T细胞进行临床前安全性评估。
Ann Transl Med. 2019 Dec;7(23):735. doi: 10.21037/atm.2019.12.03.
10
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.尽管先前使用抗CD19抗体Tafasitamab治疗复发/难治性弥漫性大B细胞淋巴瘤（DLBCL），但抗CD19嵌合抗原受体（CAR）T细胞疗法仍实现缓解。
Leuk Res Rep. 2021 Jul 14;16:100260. doi: 10.1016/j.lrr.2021.100260. eCollection 2021.
Zotero 插件